Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “buy” rating reissued by equities researchers at Panmure Gordon in a research report issued on Friday. They currently have a GBX 17.50 ($0.23) price target on the stock. Panmure Gordon’s price objective would indicate a potential upside of 19.66% from the stock’s previous close.

A number of other equities analysts have also recently commented on the company. N+1 Singer increased their target price on Ekf Diagnostics Holding PLC from GBX 18 ($0.23) to GBX 19 ($0.25) and gave the company a “buy” rating in a report on Monday, September 12th. FinnCap reissued an “under review” rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.

Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.1875 on Friday. The company’s 50 day moving average price is GBX 14.89 and its 200-day moving average price is GBX 13.22. The company’s market cap is GBX 73.70 million. Ekf Diagnostics Holding PLC has a one year low of GBX 7.00 and a one year high of GBX 23.45.

In other news, insider Mills,Christopher H. B bought 9,000,000 shares of Ekf Diagnostics Holding PLC stock in a transaction on Friday, July 15th. The stock was acquired at an average price of GBX 15 ($0.20) per share, with a total value of £1,350,000 ($1,762,172.04).

About Ekf Diagnostics Holding PLC

EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.

Receive News & Stock Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related stocks with our FREE daily email newsletter.